Form 4 Filing for Medpace Holdings, Inc.

August J. Troendle, President & CEO of Medpace Holdings, Inc., reported the sale of 10,880 shares of Common Stock on September 17, 2026. The weighted average sale price was $620.40, with individual sales ranging from $620.00 to $622.21. These transactions were executed as a limit order. Post-sale, Troendle directly owns 504,273 shares. Additionally, Troendle may be deemed to indirectly beneficially own 4,733,019 shares held by Medpace Investors, LLC, where he serves as the sole manager and controlling unit holder. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.